Enveric Biosciences + MagicMed on Recent Acquisition Announcement, Mind and Body Clinical Pipeline
SNNLive spoke with David Johnson, Chairman and CEO of Enveric Biosciences (NASDAQ: ENVB), and Dr. Joseph Tucker, CEO of MagicMed Industries (Private Company), via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):
0:38 Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives, and what this means for both firms
3:27 Dr. Tucker’s comment on Enveric Acquiring MagicMed
4:55 Quick overview of MagicMed
6:18 Clinical Pipeline
8:41 What about MagicMed’s formulations are unique and different compared to peers; approaches to using Psychedelics for medicinal purposes
11:06 Initial indications
13:32 Dr. Tucker’s background
14:52 Value catalysts moving forward
16:22 What makes the interest in psychedelics in 2020-2021 different than when Cannabis industry first came on the scene
For more information about Enveric Biosciences, please visit: https://www.enveric.com/
For more information about MagicMed Industries, please visit: https://www.magicmedindustries.com/
The interview may contain forward looking statements about Enveric Biosciences. See Enveric Biosciences’ periodic filings with Securities and Exchange Commission for more complete information.
The interview may contain forward looking statements about MagicMed Industries. See MagicMed Industries’ website for more complete information.
About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/
About MagicMed
MagicMed Industries intends to partner with pharmaceutical and other companies to develop and commercialize psychedelic-derived pharmaceutical candidates. MagicMed’s psychedelic derivatives library, the Psybrary™, is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics such as MDMA, LSD, mescaline, and ibogaine.
Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym
New videos are added almost every day to the SNN Network channel sharing fascinating stories and companies from the MicroCap stock market.
Get more SNN Network:
Website: http://stocknewsnow.com/
Follow Stock News Now: https://twitter.com/StockNewsNow
Like Stock News Now: https://www.facebook.com/SnnInc/
Follow Stock News Now on LinkedIn: https://www.linkedin.com/company/stoc……
SNN.Network is the Official YouTube Channel for the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!
source